Back to search results

Dipyridamole for Low Phosphate Levels After Kidney Transplant

This study is looking at whether a medication called Dipyridamole (75 MG) can help kidney transplant patients who have low phosphate levels (hypophosphatemia). Low phosphate can be a problem after a kidney transplant. The main goal is to see if Dipyridamole can raise your phosphate levels and reduce the need for other phosphate supplements. You might be able to join if you are an adult kidney transplant patient and do not have any reasons why you shouldn't take Dipyridamole. We don't know the current recruitment status, but the study plans to enroll 90 people.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It aims to enroll 90 adult kidney transplant patients.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your serum phosphorus levels will be measured at baseline, 1 week, 4 weeks, 8 weeks, 12 weeks, and after stopping the medication.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06824454

Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients

Recruiting
PHASE2Ages 18+InterventionalTreatment
Stanford University
~90 participants
Updated 2026-06-11 on ClinicalTrials.gov
What's tested:Dipyridamole 75 MG

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Serum Phosphorus Levels After Dipyridamole Administration
Measured over Baseline, 1 week, 4 weeks, 8 weeks, 12 weeks, and after stopping medicatio

Conditions

Hypophosphatemia
Kidney Transplantation

Explore related trials

HypophosphatemiaKidney Transplantation

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Stephan Busque, MD · PRINCIPAL_INVESTIGATOR · Stanford University

Who to contact

Pari Waghela, MS
[email protected]
650-724-8441
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adult kidney transplant patients.
No known contraindications to Dipyridamole

Exclusion

Contraindications to Dipyridamole.
Patients with delayed graft function (defined as the need for dialysis within seven days post-transplantation).
Patients requiring Plavix, direct oral anticoagulants (DOACs), or Coumadin.

What this trial measures

  • Change in Serum Phosphorus Levels After Dipyridamole AdministrationBaseline, 1 week, 4 weeks, 8 weeks, 12 weeks, and after stopping medicatio

    This study will evaluate the effectiveness of Dipyridamole in increasing serum phosphorus levels in kidney transplant recipients with hypophosphatemia.